SIXTH INTRNATIONAL LYMPHOKINE WORKSHOP

这是一份会议部分资金的申请 第六次在一系列的国际神经细胞因子研讨会。 的 1988年会议的主题是“淋巴因子受体 互动”。 研讨会将于1988年10月23日至27日在 法国依云。 本次研讨会的组织者是Dedier博士 Fradelizi和Jacques Bertoglio，实验室的 免疫学，FUNEUM/CNRS/IGR联合会，古斯塔夫研究所 法国维勒瑞夫市，埃克塞特。劳伦斯博士B。Lachman，医学博士 德克萨斯州休斯顿的安德森医院将作为美国 董事长 Fradelizi和Bertoglio博士将由一名 国际科学咨询委员会由22名 其中包括过去四年的组织者 phokine工作坊。 预计这次研讨会将 进一步推动知识的传播， 最快速发展的免疫学领域，并进一步增加 对淋巴因子在细胞中的中心作用的理解 生物学 预计这次会议将包括 关于信号机制的重要新信息 转导几种淋巴因子，也可能含有 白细胞介素1与肿瘤细胞克隆的首次报道 坏死因子受体。 国际放射因子 研讨会传统上是总理的论坛， 新里程碑的曝光。 与以往的研讨会一样， 预计会议将导致讨论， 命名，测定和一般概念的机制， 淋巴因子的作用。 此外，预计利息 在淋巴因子，特别是白细胞介素的临床应用中， 2，将大大增加临床免疫学家的出勤率， 医生

This is an application for partial funding of a meeting that will be the sixth in a series of International Lymphokine Workshops. The theme of the 1988 meetings will be "lymphokine Receptor Interactions". The workshop will be held October 23-27, 1988 in Evian, France. The organizers of this workshop are Drs. Dedier Fradelizi and Jacques Bertoglio, of the Laboratory of Immunology, Federation of INSERM/CNRS/IGR, Institute Gustave Roussy, Villejuif, France. Dr. Lawrence B. Lachman, M.D. Anderson Hospital, Houston, Texas will serve as the United States chairman. Drs. Fradelizi and Bertoglio will be assisted by an international Scientific Advisory Committee consisting of 22 members which includes the organizers of the past four Lymphokine Workshops. It is anticipated that this workshop will further advance the dissemination of knowledge in one of the most rapidly advancing areas of immunology and further increase the understanding of the central role of lymphokines in cell biology. It is anticipated that this meeting will contain significant new information concerning the mechanism of signal transduction for several lymphokines and may also contain the first reports of the cloning of the Interleukin 1 and Tumor Necrosis Factor receptors. The International Lymphokine Workshops have traditionally been the forum for the premier exposure of new milestones. As with all past workshops, this meeting is expected to lead to discussion which unify nomenclature, assays, and general concepts of the mechanism of action of lymphokines. In addition, it is anticipated that interest in the clinical application of lymphokines, particularly Interluekin 2, will greatly increase attendance by clinical immunologists and physicians.